about
Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectivesPotent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Pivotal role for decorin in angiogenesisPI3K at the crossroads of tumor angiogenesis signaling pathwaysOutcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.Andrographolide Inhibits Angiogenesis by Inhibiting the Mir-21-5p/TIMP3 Signaling Pathway.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.A Bayesian Nonparametric Approach for Functional Data Classification with Application to Hepatic Tissue Characterization.Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in MiceTargeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenograftsIdentification of an Endogenously Generated Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction Pathway.The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells.Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.Expressions of glia maturation factor-β by tumor cells and endothelia correlate with neovascularization and poor prognosis in human glioma.New advances in genitourinary cancer: evidence gathered in 2014.Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.Therapeutic application of anti-angiogenic nanomaterials in cancers.Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity.The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.Mathematical Modeling of Cellular Cross-Talk Between Endothelial and Tumor Cells Highlights Counterintuitive Effects of VEGF-Targeted Therapies.Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.S100A7: from mechanism to cancer therapy.Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.Synthesis of honokiol analogues and evaluation of their modulating action on VEGF protein secretion and telomerase-related gene expressions.In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis.How does oncogene transformation render tumor cells hypersensitive to nutrient deprivation?
P2860
Q27006707-BFAF0243-6A2A-4B61-B4BA-15374A09AD97Q27853074-A8511E38-8035-4D65-871C-44EF40A38C47Q27853358-B9AB192C-1C83-4539-BC8E-2E2651201805Q28085303-F2FA17C1-7844-41F1-9C25-74BC08DC41B3Q28396795-0B8E3AF9-9B75-4255-BC76-824502F314BEQ33441574-89204656-C3D3-4E9D-824D-E190343B6C7EQ33717796-CB60F3DE-931A-40E6-9591-4C6776E42B6CQ33824587-15337B4D-83EC-478B-9F1D-6A7D263CB7C9Q35743521-F8DD9ACB-518B-4484-A151-F5997E59F6E7Q36046096-9B714284-A147-4292-873C-BA0B0003A4B2Q36249314-47B74675-60A0-47EB-A066-919778F8A71DQ36545764-37EE85C5-FFEA-482C-BBD6-36FFFB8545D5Q36548357-9FE9223C-626C-44A8-90C6-8AE1B671A6B5Q37298189-54207AFE-3811-442F-BE80-5E65F4F8B820Q37520289-3428CFF0-59A3-4012-ADE5-023805146370Q37699121-E7BA72F7-79C3-4F6E-964B-C02B63362087Q38557894-A9C74EF3-9A11-4064-A771-BFC3CAAC2CBFQ38565385-7F7F3DC3-497F-41B3-A25E-2403592FE362Q38805034-27B91364-28F2-4D99-805F-62559F2A017BQ42333847-07A51D6D-C8AB-4414-83F6-93FC2C6061D2Q44456046-3E43BA93-54AE-4335-85E7-A905E2C6936FQ47325265-C237452C-E088-4B12-A2B5-824453A61994Q47602494-D4E9D0B7-8A96-49EA-8963-E96724430607Q47898529-C41221EC-2C29-48E1-B27F-D75705C68AAFQ47927472-66BDF394-FB98-40E8-95ED-6D6238D568F1Q48184079-69FF0073-983E-4489-8922-A37EC0D6C1ADQ49592831-4A0A8DBC-1536-423D-B51E-14D0A046C62FQ51420018-05D0AF1E-C2E6-43F5-BE98-A9889C155239Q53097666-0562809D-CD46-4354-B59B-4ED1194B3C77Q54320512-BCFA4A31-1C4F-4112-BC85-561BC8A0BA1F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antiangiogenic therapies: going beyond their limits.
@en
type
label
Antiangiogenic therapies: going beyond their limits.
@en
prefLabel
Antiangiogenic therapies: going beyond their limits.
@en
P1433
P1476
Antiangiogenic therapies: going beyond their limits.
@en
P2093
Gabriela Jiménez-Valerio
P356
10.1158/2159-8290.CD-13-0199
P577
2013-12-19T00:00:00Z